Rheumatology

Abstracts presented at EULAR 2022 focused on racial differences in gout prevalence and treatment, highlighting racial disparities in recent decades.

Based on limited existing evidence, a systematic review found no single dietary factor had a meaningful impact on rheumatic and musculoskeletal disease (RMD) outcomes.

Adults aged 50 and older who walked for exercise were less likely to develop new frequent knee pain and medial joint space narrowing.

Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).

The developers of these models said the next step is to determine how to incorporate these patient perspectives into clinical rheumatology practice.

Abstracts presented at EULAR 2022 focused on sex-related differences in inflammatory arthritis (IA) management, including adherence to electronically reporting outcomes and disparities in health care utilization.

Undifferentiated connective tissue disease (UCTD) is challenging to define but is a distinct clinical entity from connective tissue diseases (CTD).

Research supports that aquatic exercise is effective at reducing pain and disease activity and improving physical function, although it is unclear whether it is more effective than any other form of therapy for inflammatory arthritis (IA).

A letter from the American College of Rheumatology (ACR) called for drug pricing reforms, deeming them necessary to ensure the health of patients and sustainability of health care systems.

Over 48 weeks, secukinumab was shown to be effective and safe in a small study of 18 children with generalized pustular psoriasis in China.

While current data on medical cannabinoids in rheumatology is limited, findings suggest that adverse events (AEs) and drug interactions outweigh the benefits.

Researchers found that the extreme gradient boosting (XGBoost) predictor could more accurately predict rheumatoid arthritis (RA) relapse than logistic regression and random forest.

Male sex, older age, lower socioeconomic status, higher comorbidity score, and having an older or male rheumatologist were associated with the reduced likelihood of continuing with rheumatoid arthritis (RA) treatment.

According to the authors, sex-based differences may be a cause of higher rheumatoid arthritis (RA) disease activity.

Among patients with rheumatoid arthritis (RA) in clinical remission, patient-physician discordance when assessing disease activity may be associated with the inability to achieve remission.

A meta-analysis found that a third of patients with rheumatoid arthritis (RA) in a sample had metabolic syndrome, which can double the risk of cardiovascular outcomes in this population.

Results from the CHOICE study suggest that both a 150 mg and 300 mg dose of secukinumab improved symptoms of psoriatic arthritis (PsA) in biologic-naïve patients, with higher response rates for the 300 mg dose.

Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Researchers found no association between the use of tofacitinib, tocilizumab, or tumor necrosis factor (TNF) inhibitors and risk of developing Alzheimer disease and related dementia (ADRD) among older patients with rheumatoid arthritis (RA).

Age at symptom presentation was significantly associated with longer symptom duration for children with juvenile idiopathic arthritis (JIA).

Complications were significantly associated with low height, high-dose prednisolone use, and progression of cervical spine lesions in early disease stages of rheumatoid arthritis (RA).

Research shows that disease activity level did not correlate with fat mass percentage among individuals with rheumatoid arthritis (RA).

Patients aged 75 years and older who received a rheumatoid arthritis (RA) diagnosis 2 years ago or less had the highest risk of developing primary open-angle glaucoma (POAG).

Variations between current core outcome sets and how trials are actually measuring self-management among patients with inflammatory arthritis (IA) show the need for further established outcome domains.

The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes compared with in-person monitoring.

The American College of Rheumatology (ACR) has released updated guidelines on pharmacologic and nonpharmacologic treatments for juvenile idiopathic arthritis.

According to the study, rheumatoid arthritis (RA)-associated autoimmunity was not linked to increased cardiovascular (CV) event risk, suggesting systemic inflammation is likely required for precipitating CV events.

According to data from the Global Burden of Disease study 2019, osteoarthritis (OA) is still globally prevalent and is expected to increase due to rising obesity and the aging of populations.